Table 3.
Pharmacokinetic parameters of alirocumab following injection of a single 75 mg dose into three different injection sites
| Alirocumab 75 mg SC | |||
|---|---|---|---|
| Abdomen (n = 20) | Upper arm (n = 20) | Thigh (n = 20) | |
| Cmax, mg/L | 8.18 (2.51) | 6.77 (2.02) | 7.13 (2.21) |
| tmax, days; median (range) | 2.96 (1.95–7.01) | 6.95 (1.96–10.08) | 3.06 (2.15–8.11) |
| t1/2z, days | 6.03 (1.11) | 6.66 (0.97) | 5.77 (1.59) |
| AUC, mg day/L | 129 (35.7) | 130 (42.0) | 115 (44.4) |
| CL/F, L/day | 0.63 (0.18) | 0.63 (0.20) | 0.78 (0.31) |
| Vss/F, L | 7.28 (2.46) | 8.54 (3.40) | 8.92 (4.66) |
| MRT, days | 11.6 (1.83) | 13.5 (2.35) | 11.9 (2.49) |
Values are mean (SD), unless otherwise stated.
Cmax, maximum concentration; tmax, time to reaching Cmax; t1/2z, half-life; AUC, area under the serum concentration versus time curve; CL/F, clearance relative to bioavailability; Vss/F, distribution volume at the steady state relative to bioavailability; MRT, mean residence time; SC, subcutaneous.